Previous Close | 7.00 |
Open | 6.93 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's Range | 7.00 - 7.25 |
52 Week Range | 3.06 - 7.55 |
Volume | |
Avg. Volume | 227,485 |
Market Cap | 246.462M |
Beta (5Y Monthly) | 1.16 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.88 |
Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.40 |
This week we saw the AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) share price climb by 20%. But will that heal all the...
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 - BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has enter
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. “Category 1 is the highest Category recommendation offered by NCCN, which is bas